Cullinan Therapeutics Inc

CGEM

Add to Watchlist

15.730USD

-0.420-2.60%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Cullinan Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

18 / 382

Overall Ranking

106 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cullinan Therapeutics Inc Highlights

StrengthsRisks

Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -4.23, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 64.85M shares, decreasing 18.37% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 5.55K shares of this stock.

Analyst Rating

Based on 13 analysts

Strong Buy

Current Rating

35.000

Target Price

+116.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Cullinan Therapeutics Inc is 5.87, ranking 305 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is average.

Score

Industry at a Glance

Previous score

5.87

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.16

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Cullinan Therapeutics Inc is 7.72, ranking 84 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.23, which is -342.11% below the recent high of 10.23 and -122.20% above the recent low of -9.39.

Score

Industry at a Glance

Previous score

7.72

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 18/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Cullinan Therapeutics Inc is 9.08, ranking 16 out of 382 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 53.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

9.08

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Cullinan Therapeutics Inc is 9.30, ranking 17 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.37 and the support level at 13.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.45

Change

-0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Cullinan Therapeutics Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 106.02%, representing a quarter-over-quarter decrease of 19.74%. The largest institutional shareholder is PRFDX, holding a total of 866.95K shares, representing 1.41% of shares outstanding, with 6491.59% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

8.96M

--

MPM BioImpact LLC

7.65M

--

BVF Partners L.P.

5.75M

--

BlackRock Institutional Trust Company, N.A.

3.89M

+5.52%

Kynam Capital Management LP

3.11M

+35.27%

Blue Owl Capital Holdings LP

2.35M

-6.37%

State Street Investment Management (US)

2.20M

+31.00%

Affinity Asset Advisors LLC

1.93M

+632.37%

RTW Investments L.P.

1.71M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cullinan Therapeutics Inc is 3.49, ranking 133 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -0.05. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Cullinan Therapeutics Inc

CGEM

7.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment